The aim of this study was to evaluate taste perception, salivary flow rate and oral pathologies in three different groups of patients undergoing hematopoietic SCT (HSCT) classified according to time post transplant. Group I (n ¼ 20) up to 150 days after HSCT, group II (n ¼ 20) between 151 and 1095 days and group III (n ¼ 21) more than 1095 days. Taste acuity was measured by four basic tastes of four solutions, in three concentrations (M): NaCl, sucrose, citric acid and caffeine. Patients classified flavors as sweet, sour, salty, bitter and without flavor. The intensity was considered high, medium and low. Unstimulated saliva was collected and salivary flow rates (ml/min) were determined. Of 61 patients, 31 had chronic GVHD. For the sweet solution, the high and low concentrations represented a challenge for those patients. No patients were sensitive to the low concentration of caffeine solution (P ¼ 0.05). Saliva flow rate was diminished in 10 of 61 (16%) patients and hyposalivation was more intense in groups II/III (P ¼ 0.007). There was no correlation between taste dysfunction and oral chronic GVHD. The results indicated taste alterations only for the sweet and salty tastes even in patients up to 3 years after HSCT and may not correlate with oral chronic GVHD and with hyposalivation.
Introduction
The sense of taste is a sensorial system modality that has a critical role in the life and nutritional status of the human being. The gustatory system can detect four well-characterized taste qualities: sweet, sour, bitter and salty. 1 These sensations are mediated by specialized neuroepithelial cells that are organized in the taste buds on the surface of the tongue. 2 Taste disorders are prevalent in oncology patients and often have a negative effect on quality of life and nutrition status. 3 However, the prevalence of taste dysfunction may be underestimated, as the true prevalence of these disorders is difficult to assess. 4 Taste alterations may occur as a result of the cancer itself, treatment of the cancer or other social and emotional factors. 5 Loss or change in taste perception, dry mouth and other oral problems are frequent complaints among most patients undergoing allogeneic hematopoietic SCT (HSCT). 6 Increasing numbers of HSCTs are being performed, and improved outcomes are resulting in a growing number of survivors. GVHD is a major complication in stem cell transplant recipients and can affect many organs, including the oral cavity, [7] [8] [9] with a reported morbidity and mortality incidence of 40-70%. 10 This disease is mediated by autoreactive T lymphocytes that infiltrate various target organs and tissues, including the oral mucosa and salivary glands, leading to salivary hypofunction and oral damage. 7 Oral manifestations of chronic GVHD (cGVHD) include lichenoid lesions, mucosal atrophy, ulceration, salivary gland hypofunction and taste disturbances. Oral pain and food sensitivity are common and can be associated with a decrease in food intake and weight loss. 7 Avsar et al. 11 noted that the significant weight loss and malnutrition in patients undergoing chemotherapy could be associated with a lack of desire for food induced by nausea, smell and taste dysfunctions.
However, there is no consensus as to duration of taste dysfunction in post-HSCT patients, or the influence of oral and systemic pathologies and their association with taste changes. The aim of this study was to evaluate patients undergoing ablative or reduced-intensity HSCT, with regard to the influence of treatment timing, presence of oral GVHD and salivary flow rate on taste perception.
Patients and methods
This study was a prospective cross-sectional study carried out between March 2006 and April 2008 at the Bone Marrow Transplantation (BMT) Unit of the University of Campinas (Sa˜o Paulo, Brazil), which enrolled 61 patients, undergoing allogeneic or low reduced-intensity HSCT.
Patients were classified into three groups with respect to time after transplant. Group I (n ¼ 20) up to 150 days after HSCT, group II (n ¼ 20) between 151 and 1095 days and group III (n ¼ 21) more than 1095 days of HSCT.
Clinical data were obtained from the medical records of patients, available either through paper or by electronic registries. This study was approved by the Research Ethics Committee of the School of Medicine, and all patients or their legal representatives provided written, informed consent before participating in the study.
Oral examination
Oral clinical conditions were evaluated by radiography and using a mouth mirror, a probe and artificial light at the dental unit. The oral cavity was examined in order to verify the presence of oral manifestations of cGVHD and acute GVHD, or other possible oral pathologies related to treatment.
Oral cGVHD was evaluated using clinical parameters including presence of inflammation and atrophy, hyperkeratotic changes, pseudomembranous ulceration, fibrosis and mucoceles. 8, 12, 13 Survey A survey was carried out based on the taste change questionnaire described by Wickham 6 and Mattson. 14 This questionnaire contained questions regarding issues that could influence taste perception, such as chewing difficulties, dental diseases, tobacco and alcohol use, dry mouth, xerostomia, oral pain, nausea, vomiting, desire to eat, dysgeusia and regular prescribed medications ( Table 1) . Loss of weight was also considered in this survey. Patients were requested to complete the questionnaire on the day of taste evaluation.
Taste and saliva tests Measurement of unstimulated salivary flow rate. Unstimulated saliva was collected before taste evaluation and 30 min after most recent dental brushing, according to Nagler. 9 The procedure consisted of salivary expectoration, every 30 s for 5 min, into a sterile pre-weighed plastic container (Figure 1d ). Patients were asked not to swallow during the collection period.
All samples were measured using a digital analogical balance in milligrams and the volumetric measure was taken in milliliters. Salivary flow rates were determined in milliliters per minute (ml/min). Hyposalivation was considered when the salivary flow rate result was o0.1 ml/min. 15 
Solution preparation
All chemicals used for detection thresholds were graded reagents: sucrose (sweet), citric acid (sour), sodium chloride (salty) and caffeine (bitter) supplied by Cromoline (Diadema, Sa˜o Paulo, Brazil) and were weighed on a precision analytical balance. Distilled water free of solutes was used to prepare three different concentrations of each solution on the day of evaluation (Table 2) . Concentrations were based on previous studies 14, 16 and solutions were stored in 50 ml glass bottles. Stimuli were distributed to each participant in 5 ml aliquots in plastic glasses (Table 2 ; Figure 1a ). Taste acuity evaluations were carried out throughout the same morning, at least 1 h after eating or drinking and dental brushing, at room temperature. Taste samples were systematically provided in a plastic glass previously nominated as 'A' for low intensity, 'E' as medium or 'O' as high concentration. These samples were randomly offered to the patient to 'swish' and expectorate after any taste perception. Patients were then requested to determine the taste (as sweet, bitter, salt and sour, or without taste) and to classify taste for intensity: 'low', 'medium' or 'high' (Figure 1b) . The mouth was rinsed with distilled water between each tasting.
Data collection and statistical analysis Data were collected from January 2007 to June 2008. Dichotomous variables were compared using Fisher's test or w 2 test, whereas continuous variables were compared using the Kruskal-Wallis test. P-values were considered statistically significant with values o0.05. Statistical analysis was carried out using SPSS 15.0 (SPSS Inc, Chicago, IL, USA). (Table 3) . Conditioning regimens and GVHD prophylaxis were specific for the underlying diseases. Patient groups, cGVHD prophylaxis and the stem cell source are shown in Table 4 .
Oral GVHD Of the 35 (55.7%) patients who developed oral cGVHD, 3 (5%) had localized cGVHD and 32 (52.4%) extensive cGVHD. However, on the day of the oral clinic evaluation, reticular lichenoid lesions were found in 23 (65.71%) patients, whereas 8 (22.85%) patients had atrophic lesions. The distribution of cGVHD according to study timing showed that cGVHD was presented in groups I-III (Figure 2 ).
Questionnaire
The questionnaire indicated that of the 61 patients studied, 20 (32.8%) smoked and 29 (47.5%) drank alcohol socially before the transplant. In total, 46 (75.4%) patients took regular prescribed medications including drugs with a recognized influence on taste perception, such as analgesics, antibiotics, antihypertensives, muscle relaxants and antidepressants 17 (Table 1) . No topical medication was used during the period of study. This was observed in 18 patients from group I, 15 from group II and 7 from group, with a significant statistical difference among the three groups (Po0.001). Difficulties in chewing, swallowing and in speaking were reported by 11, 8 and 5 patients, respectively. However, only chewing difficulties made a statistical difference in patients from group II (P ¼ 0.04). The presence of nausea and vomiting were reported differently among the three groups (P ¼ 0.03 and P ¼ 0.04, respectively). Nausea was reported by 10 patients from group I and 8 from group II, and it appeared to have a positive correlation with the use of drugs that were related to altered taste (P ¼ 0.06). Similarly, vomiting was observed in eight patients from group I and three from group II. Changes in olfaction were reported by 29 (47.5%) patients, whereas 37 (60.5%) noticed alterations in taste. Changes in smell were significantly reported by 11 patients from group I, 12 from group II and 6 from group III (P ¼ 0.09).
In general, xerostomia was the most important patient complaint and was observed in 34 (55.7%) patients. In addition, 18 (29.50%) patients complained of pain and a burning sensation, with 10 of 18 (55.55%) from group II Table 5 .
Weight loss was cross-checked between the last measurement before the transplant and the measurement on the day of the study evaluation. Weight loss was observed in 36 (59%) patients and the median weight loss was 8 kg (0.5-26). From group I, 17 of 20 (85%) patients experienced weight loss with a median of 4.4 kg, whereas from group II 13 of 20 (65%) lost a median of 5.3 kg and in group III 6 of 21 patients experienced a median weight loss of 3.5 kg. The results also showed that patients who took drugs that are related to altered taste had a higher median weight loss (P ¼ 0.02).
Fifteen (24.6%) patients reported a subjective increase in taste perception (5 from group I, 6 from group II and 4 from group III), whereas 22 (36.1%) patients (10 from groups I, 9 from group II and 3 from group III), described a decrease in taste perception after HSCT, probably as a consequence of using prescribed medications related to altered taste (P ¼ 0.04).
Salivary evaluation
Xerostomia was observed in 34 (55.7%) of the patients enrolled in this study and was their main complaint. There could have been an association with the prescribed medications that 46 patients were taking. Of these, 42 (91.3%) patients were taking drugs that could cause salivary hypofunction such as antiemetics, antihypertensives and antidepressants. This was observed in 16 patients from group I, 15 from group II and 11 from group III. Although salivary flow rate was diminished in only 10 (16.4%) patients, intense hyposalivation was observed in groups I and II (P ¼ 0.007), without any correlation with prescribed medications (P ¼ 0.6) (Figure 3 ).
Taste evaluation
In general, patients were able to detect all four tastes: sweet, salty, bitter, and sour at every concentration tasted. However, when the solutions were analyzed singly, some differences were found in taste perception among the three groups. For taste intensity, high and low concentration of sucrose represented a challenge for patients from groups II and III (P ¼ 0.04 and 0.05), especially in those patients who were taking prescribed medications related to altered taste (P ¼ 0.04). On the other hand, perception of high sucrose concentrations was better observed in the same two groups (P ¼ 0.07) ( Table 6 ). Perception for a medium concentration of salty solutions was better perceived by groups II and III (P ¼ 0.08) ( Table 6 ). None of the patients were able to perceive low concentrations of bitter solutions (P ¼ 0.05) ( Table 7) . There was no difference in tasting intensity for the different concentrations of sour, bitter and salty among these groups. No correlations of intensity of taste perception were found when compared with the presence of oral cGVHD and salivary flow rate. Incidence of oral chronic GVHD inpatients of Groups I, II and III. Alterations in the perceived taste of food are one of the major causes of food aversion in cancer patients and can result in decreased energy intake and anorexia. 19 The sensation of taste involves stimulation specific to chemoreceptors (taste buds), adequate saliva, and intact neural pathways and smell function. 6 As smell and taste are closely linked and both are required for the full sensation of flavor, changes in the smelling senses of the patient can affect the taste of food. 20 However, the etiology of taste disorders in patients receiving HSCT seems to be multifactorial 21 and is not only a matter of damage to the taste buds induced by cytotoxic antineoplasic treatments. 4 Hyposalivation during cancer therapy, mouth breathing and side effects of a number of medications may lead to changes in taste. 6 Damage to salivary glands may reduce saliva, and hence the tasting solution. 21 For this study, the methodology used was based on measurements of the detection and recognition thresholds of chemical reagents for sucrose (sweet), citric acid (sour), sodium chloride (salt) and caffeine (bitter).
The present results indicate that post-HSCT taste alterations are not correlated with the presence of oral cGVHD and hyposalivation. Conditioning regimens can promote oral toxicity and also injure salivary glands. 22 Salivary damage could be observed in the scintigraphy of patients 100 days after HSCT and could be prompted by the presence of cGVHD.
Although hyposalivation was observed in only 10 patients in this study, xerostomia was one of the most important complaints also in the group that had had HSCT for longer than 3 years. There was a possible correlation with oral cGVHD observed in these patients or it could have been a late effect of GVHD.
Chronic GVHD results in mucosal and salivary gland damage that can lead to xerostomia and a consequently prolonged risk of oral infection, increased risk of dental caries and difficulties with mastication, swallowing and speech. 21 In this study, five patients from group II reported significant difficulty in chewing, probably as a consequence of oral cGVHD, also observed in 14 patients from this group. Similarly, pain and a burning sensation, which are subjective complaints of oral cGVHD, were also observed in 10 patients from group II and 8 patients from group III (P ¼ 0.001) in this study.
Changes in the perception of taste in patients with cancer may be related to other factors, including progressive malignant disease, surgery, radiation therapy and drugs. 23 Drugs other than chemotherapeutic agents, including some antibiotics, analgesics, antihypertensives and cardiac medications, muscle relaxants, antidepressants and anticonvulsants, can alter taste. 4, 17 Medications are known to stimulate the taste system via saliva and blood. Other pathways by which substances can enter the mouth include poor oral hygiene, viral or fungal infections of the oral cavity and reflux via blood. 4 During systemic stimulation, Salivary Flow Rate ml/minute Figure 3 Mean value of salivary flow rate (ml/min) for the three groups.
drugs diffuse from the blood to the taste cells and change taste sensations. 3 In the group of patient enrolled in this study, 46 (75.4%) were receiving one or more drugs that could influence taste perception. Our study showed that the using of prescribed medications that are related to altered taste could be associated with difficultly in the ability to perceive taste intensity of high and low concentrations of sucrose (P ¼ 0.04).
In a study of allogeneic HSCT and auto-HSCT patients, Marinone et al. 16 showed that taste dysfunction can be associated with allogeneic HSCT, as most patients undergoing allogeneic HSCT had a persistent, selective alteration in salty and sour taste. However, in this study, taste alterations were observed for sweet and salty tastes up to 3 years after HSCT.
Mattsson et al. noted that taste changes could be transient and resolve after the acute period of HSCT. The authors showed taste recovery after 1 year of HSCT. Comeau et al. proposed that the significant weight loss and malnutrition in patients undergoing HSCT could be associated with decreased smell and taste sensitivity. This study enrolled 15 HCST patients and showed that 10 patients had lost taste acuity during the aplastic phase. Nevertheless, in 80% of patients this feature normalized after 1 year from HSCT.
Decreased taste sensitivity is not only distressing for patients, affecting their quality of life, but can also lead to food aversion resulting in weight loss and nutritional decline. 24 Malnutrition is present in these patients as they can experience prolonged poor appetite with vomiting and diarrhea. 25 It is well known that underweight HSCT patients are more likely to experience a relapse after transplantation than do normal weight patients. 26 In this study, weight loss was observed in 36 patients after HSCT and this could be related to changes in salty and sweet tastes. Decreased energy intake and nausea were reported in this study by 10 patients from group I and 8 from group II, whereas vomiting was observed in 8 patients from group I and 3 from group II, all of whom have nutritional implications.
In summary, this study found taste dysfunction in all groups of patients after HSCT, indicating that taste changes can be permanent and can also occur as a late complication of HSCT.
Conclusion
Taste changes have the potential to negatively affect physiological, psychological, social and functional status, thereby influencing overall quality of life. Decreased taste Table 7 Taste evaluation for the NaCl and caffeine solutions for the three groups post-HSCT Abbreviation: HSCT ¼ hematopoietic SCT. sensitivity can lead to anorexia, food aversion and inadequate nutritional intake. 6 A thorough knowledge of the nature, frequency, severity and duration of alterations in taste and possible treatments may improve the life quality of HSCT patients.
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